HUE036928T2 - Nátrium-(2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorbenzil)karbamoil)- 2,3,4,5,7,9,13,13a-oktahidro-2,5-metanopirido[l',2':4.5]pirazino[2,l-b]oxazepin-8-olát - Google Patents
Nátrium-(2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorbenzil)karbamoil)- 2,3,4,5,7,9,13,13a-oktahidro-2,5-metanopirido[l',2':4.5]pirazino[2,l-b]oxazepin-8-olátInfo
- Publication number
- HUE036928T2 HUE036928T2 HUE15739063A HUE15739063A HUE036928T2 HU E036928 T2 HUE036928 T2 HU E036928T2 HU E15739063 A HUE15739063 A HU E15739063A HU E15739063 A HUE15739063 A HU E15739063A HU E036928 T2 HUE036928 T2 HU E036928T2
- Authority
- HU
- Hungary
- Prior art keywords
- methanopyrido
- trifluorobenzyl
- oxazepine
- olate
- octahydro
- Prior art date
Links
- -1 (2,4,6-trifluorobenzyl) carbamoyl Chemical group 0.000 title 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015245P | 2014-06-20 | 2014-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE036928T2 true HUE036928T2 (hu) | 2018-08-28 |
Family
ID=53674269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15739063A HUE036928T2 (hu) | 2014-06-20 | 2015-06-19 | Nátrium-(2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorbenzil)karbamoil)- 2,3,4,5,7,9,13,13a-oktahidro-2,5-metanopirido[l',2':4.5]pirazino[2,l-b]oxazepin-8-olát |
Country Status (45)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015014714B1 (pt) | 2012-12-21 | 2018-12-26 | Gilead Sciences, Inc. | compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| PL3316868T3 (pl) * | 2015-06-30 | 2020-10-19 | Gilead Sciences, Inc. | Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę |
| PE20181207A1 (es) | 2015-11-09 | 2018-07-23 | Gilead Sciences Inc | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3506902A4 (en) * | 2016-08-31 | 2020-04-22 | VIIV Healthcare Company | COMBINATIONS AND USES AND TREATMENTS THEREOF |
| WO2018064071A1 (en) * | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| CN107445994A (zh) * | 2017-05-31 | 2017-12-08 | 北京阜康仁生物制药科技有限公司 | 替诺福韦艾拉酚胺半富马酸盐新晶型 |
| DK3749673T3 (da) | 2018-02-09 | 2022-06-20 | Sandoz Ag | Krystallinsk form af bictegravir-natrium |
| WO2019207602A1 (en) | 2018-04-26 | 2019-10-31 | Mylan Laboratories Limited | Polymorphic forms of bictegravir and its sodium salt |
| WO2020003151A1 (en) | 2018-06-28 | 2020-01-02 | Honour Lab Limited | Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form |
| KR102879944B1 (ko) * | 2018-09-19 | 2025-11-03 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 예방용 인테그라제 억제제 |
| EP3653629A1 (en) | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
| US12195480B2 (en) | 2019-02-07 | 2025-01-14 | Cipla Limited | Polymorphs of integrase inhibitor |
| AU2020245350B2 (en) | 2019-03-22 | 2023-04-20 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2020255004A1 (en) * | 2019-06-18 | 2020-12-24 | Laurus Labs Limited | Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof |
| CN111978333B (zh) * | 2019-09-30 | 2021-06-18 | 常州制药厂有限公司 | Bictegravir钠盐的晶型A、制备方法及用途 |
| BR112022015771A2 (pt) | 2020-02-24 | 2022-10-11 | Gilead Sciences Inc | Compostos tetracíclicos para tratar a infecção por hiv |
| EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CN113698420A (zh) * | 2020-05-22 | 2021-11-26 | 上海迪赛诺生物医药有限公司 | 比克替拉韦钠的新晶型及其制备方法 |
| KR20230079137A (ko) | 2020-09-30 | 2023-06-05 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| CN112409380A (zh) * | 2020-12-10 | 2021-02-26 | 上海迪赛诺生物医药有限公司 | 比克替拉韦钠的新晶型的制备方法及其应用 |
| ES2968058T3 (es) | 2021-01-19 | 2024-05-07 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de los mismos |
| WO2022224120A1 (en) * | 2021-04-19 | 2022-10-27 | Honour Lab Limited | Polymorphic forms of bictegravir potassium |
| TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2023248240A1 (en) | 2022-06-21 | 2023-12-28 | Mylan Laboratories Limited | Polymorphic forms of bictegravir sodium |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| EP4577242A1 (en) | 2022-08-26 | 2025-07-02 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| WO2024220624A1 (en) | 2023-04-19 | 2024-10-24 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250120989A1 (en) * | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788516A (fr) | 1971-09-10 | 1973-03-07 | Lonza Ag | Procede de fabrication d'esters alcoxyacetylacetiques |
| GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
| DE3900736A1 (de) | 1989-01-12 | 1990-07-26 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch enthaltend einen mehrfunktionellen (alpha)-diazo-(beta)-ketoester, verfahren zu dessen herstellung und strahlungsempfindliches aufzeichnungsmaterial enthaltend dieses gemisch |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| DE4014649A1 (de) | 1990-05-08 | 1991-11-14 | Hoechst Ag | Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| WO2000027823A1 (en) | 1998-11-09 | 2000-05-18 | James Black Foundation Limited | Gastrin and cholecystokinin receptor ligands |
| GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
| TR200101886T2 (tr) | 1998-12-25 | 2001-12-21 | Shionogi & Co., Ltd. | HIV integrazını önleme aktivitesi olan aromatik heterosikl bileşimleri. |
| US20040039060A1 (en) | 2000-06-14 | 2004-02-26 | Ryuichi Kiyama | Inhibitor for enzyme having two divalent metal ions as active centers |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| PL370355A1 (en) | 2001-10-03 | 2005-05-16 | Ucb, S.A. | Pyrrolidinone derivatives |
| HU230248B1 (hu) | 2001-10-26 | 2015-11-30 | Msd Italia S.R.L. | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| EP3406596A1 (en) | 2002-11-20 | 2018-11-28 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| KR20090053867A (ko) | 2003-01-14 | 2009-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| EP1713773A4 (en) | 2004-01-30 | 2009-09-23 | Merck & Co Inc | N-BENZYL-3,4-DIHYDROXYPYRIDINE-2-CARBOXYLIC AMID AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXYLIC AMIDE COMPOUNDS SUITABLE AS INHIBITORS OF THE HIV INTEGRASE |
| AU2005220767A1 (en) | 2004-03-09 | 2005-09-22 | Merck & Co., Inc. | HIV integrase inhibitors |
| WO2006028523A2 (en) | 2004-04-29 | 2006-03-16 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
| US7538112B2 (en) | 2004-05-07 | 2009-05-26 | Merck & Co., Inc. | HIV integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| TR201906416T4 (tr) | 2004-07-27 | 2019-05-21 | Gilead Sciences Inc | Hiv inhibitörü bileşiklerin fosfonat analogları. |
| JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| JP2006118669A (ja) | 2004-10-25 | 2006-05-11 | Sanoh Industrial Co Ltd | 樹脂チューブ |
| WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| US7858788B2 (en) | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| SI3372281T1 (sl) * | 2005-04-28 | 2021-11-30 | Viiv Healthcare Company | Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze |
| CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
| WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| JP2009502964A (ja) | 2005-07-27 | 2009-01-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体 |
| CA2626956A1 (en) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| EA018544B1 (ru) | 2005-12-30 | 2013-08-30 | Джилид Сайэнс, Инк. | Способ лечения ретровирусной инфекции |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US20090018162A1 (en) | 2006-02-01 | 2009-01-15 | Yuji Matsuzaki | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| RS54047B1 (sr) | 2006-03-06 | 2015-10-30 | Japan Tobacco Inc. | Postupak za dobijanje jedinjenja 4-oksohinolina |
| CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7888375B2 (en) | 2006-07-19 | 2011-02-15 | The University Of Georgia Research Foundation, Inc | Pyridinone diketo acids: inhibitors of HIV replication |
| PT2069280E (pt) | 2006-09-12 | 2015-06-08 | Gilead Sciences Inc | Processo e intermediários para preparar inibidores de integrase de vih |
| JP2010506913A (ja) | 2006-10-18 | 2010-03-04 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤 |
| ES2603645T3 (es) | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de agentes terapéuticos |
| US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
| MX2009013829A (es) | 2007-06-29 | 2010-03-10 | Gilead Sciences Inc | Composiciones terapeuticas y su uso. |
| AR067184A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| WO2009018320A1 (en) | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010005334A (es) | 2007-11-16 | 2010-05-27 | Boehringer Ingelheim Int | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2010011813A1 (en) | 2008-07-23 | 2010-01-28 | Alkermes, Inc. | Complex of trospium and pharmaceutical compositions thereof |
| EP2660239B1 (en) | 2008-07-25 | 2016-11-23 | VIIV Healthcare Company | Chemical compounds as synthetic intermediates |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
| WO2010011812A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| KR101678563B1 (ko) | 2008-12-11 | 2016-11-22 | 비이브 헬쓰케어 컴퍼니 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체 |
| CA2744019C (en) | 2008-12-11 | 2017-03-14 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| JP5697163B2 (ja) | 2009-03-26 | 2015-04-08 | 塩野義製薬株式会社 | 置換された３−ヒドロキシ−４−ピリドン誘導体 |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| RS57244B1 (sr) | 2009-06-15 | 2018-07-31 | Shionogi & Co | Supstituisani policiklički derivati karbamoilpiridona |
| US8637674B2 (en) | 2009-09-02 | 2014-01-28 | Ewha University-Industry Collaboration Foundation | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same |
| SI2932970T1 (en) | 2010-01-27 | 2018-07-31 | Viiv Healthcare Company | Antiviral therapy |
| MX2012009869A (es) | 2010-02-26 | 2012-09-12 | Japan Tobacco Inc | Derivado de 1, 3,4, 8-tetrahidro-2h-pirido[1, 2-a]pirazina y sus uso como inhibidor de la integrasa del vih. |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| JP5984218B2 (ja) | 2010-07-02 | 2016-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｉｄｓを処置するためのナフト−２−イル酢酸誘導体 |
| AP2013006707A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds |
| US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP2602260B1 (en) | 2010-08-05 | 2016-09-28 | Shionogi&Co., Ltd. | Process for preparing compound having hiv integrase inhibitory activity |
| HUE039859T2 (hu) | 2010-09-24 | 2019-02-28 | Shionogi & Co | Helyettesített policiklusos karbamoil-piridon-származék prodrug |
| WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
| WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| US9121496B2 (en) | 2011-06-29 | 2015-09-01 | Arvinmeritor Technology, Llc | Drive axle system and a method of control |
| WO2013006738A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2013038407A1 (en) * | 2011-09-14 | 2013-03-21 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
| US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
| US9643974B2 (en) | 2011-12-12 | 2017-05-09 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
| EA201490647A1 (ru) | 2012-04-20 | 2014-12-30 | Джилид Сайэнс, Инк. | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| EP2875024A4 (en) | 2012-07-20 | 2015-12-23 | Merck Sharp & Dohme | HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES |
| EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | SUBSTITUTED NAPHTHYRIDEINDION DERIVATIVES AS HIV INTEGRASE INHIBITORS |
| AU2013296289B2 (en) | 2012-08-03 | 2017-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| ES2615302T3 (es) | 2012-11-08 | 2017-06-06 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heteroarilo útiles como modulares de cinasa |
| SG10201704467SA (en) | 2012-12-14 | 2017-06-29 | Glaxosmithkline Llc | Pharmaceutical compositions |
| US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| US20160000721A1 (en) | 2012-12-21 | 2016-01-07 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
| US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| BR112015014714B1 (pt) | 2012-12-21 | 2018-12-26 | Gilead Sciences, Inc. | compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico |
| WO2014104279A1 (ja) | 2012-12-27 | 2014-07-03 | 日本たばこ産業株式会社 | 置換されたスピロピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途 |
| EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2015110897A2 (en) | 2014-01-21 | 2015-07-30 | Laurus Labs Private Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| WO2016102078A1 (en) | 2014-12-24 | 2016-06-30 | Ratiopharm Gmbh | Solid state forms of dolutegravir sodium |
| PE20181207A1 (es) | 2015-11-09 | 2018-07-23 | Gilead Sciences Inc | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana |
-
2012
- 2012-06-06 NO NO12796397A patent/NO2717902T3/no unknown
-
2015
- 2015-06-17 TW TW108122266A patent/TWI731354B/zh active
- 2015-06-17 TW TW104119604A patent/TWI673274B/zh active
- 2015-06-17 UY UY0001036177A patent/UY36177A/es not_active Application Discontinuation
- 2015-06-18 AR ARP150101953A patent/AR100903A1/es active IP Right Grant
- 2015-06-18 MA MA40239A patent/MA40239B1/fr unknown
- 2015-06-19 CU CU2016000187A patent/CU24478B1/es unknown
- 2015-06-19 MY MYPI2016704591A patent/MY186696A/en unknown
- 2015-06-19 MX MX2016016059A patent/MX369555B/es active IP Right Grant
- 2015-06-19 MX MX2019013380A patent/MX383272B/es unknown
- 2015-06-19 UA UAA201613232A patent/UA118480C2/uk unknown
- 2015-06-19 PL PL15739063T patent/PL3157932T3/pl unknown
- 2015-06-19 ME MEP-2018-73A patent/ME03037B/me unknown
- 2015-06-19 EA EA201692414A patent/EA030967B1/ru unknown
- 2015-06-19 SG SG11201610211QA patent/SG11201610211QA/en unknown
- 2015-06-19 LT LTEP15739063.4T patent/LT3157932T/lt unknown
- 2015-06-19 EP EP15739063.4A patent/EP3157932B1/en not_active Revoked
- 2015-06-19 MD MDA20170006A patent/MD4584C1/ro active IP Right Grant
- 2015-06-19 TR TR2018/02179T patent/TR201802179T4/tr unknown
- 2015-06-19 PL PL17204116.2T patent/PL3321270T3/pl unknown
- 2015-06-19 WO PCT/US2015/036757 patent/WO2015196116A1/en not_active Ceased
- 2015-06-19 RS RS20180286A patent/RS56950B1/sr unknown
- 2015-06-19 DK DK15739063.4T patent/DK3157932T3/en active
- 2015-06-19 KR KR1020177001377A patent/KR101899803B1/ko active Active
- 2015-06-19 NZ NZ727155A patent/NZ727155A/en unknown
- 2015-06-19 EP EP17204116.2A patent/EP3321270B1/en active Active
- 2015-06-19 HU HUE15739063A patent/HUE036928T2/hu unknown
- 2015-06-19 ES ES15739063.4T patent/ES2660862T3/es active Active
- 2015-06-19 SM SM20180053T patent/SMT201800053T1/it unknown
- 2015-06-19 MA MA044221A patent/MA44221A/fr unknown
- 2015-06-19 PE PE2016002742A patent/PE20170150A1/es unknown
- 2015-06-19 CR CR20160589A patent/CR20160589A/es unknown
- 2015-06-19 AP AP2016009591A patent/AP2016009591A0/en unknown
- 2015-06-19 CN CN201580033152.4A patent/CN106459085B/zh active Active
- 2015-06-19 US US14/744,915 patent/US9708342B2/en active Active
- 2015-06-19 EP EP24215783.2A patent/EP4523758A3/en active Pending
- 2015-06-19 JP JP2016574180A patent/JP6334007B2/ja active Active
- 2015-06-19 BR BR122021025861-9A patent/BR122021025861B1/pt active IP Right Grant
- 2015-06-19 SI SI201530163T patent/SI3157932T1/en unknown
- 2015-06-19 ES ES17204116T patent/ES3010114T3/es active Active
- 2015-06-19 MD MDA20180037A patent/MD20180037A2/ro not_active Application Discontinuation
- 2015-06-19 CA CA2950307A patent/CA2950307C/en active Active
- 2015-06-19 HR HRP20180455TT patent/HRP20180455T1/hr unknown
- 2015-06-19 EA EA201891464A patent/EA201891464A1/ru unknown
- 2015-06-19 BR BR112016029605-2A patent/BR112016029605B1/pt active IP Right Grant
- 2015-06-19 PT PT157390634T patent/PT3157932T/pt unknown
- 2015-06-19 CN CN201910478532.9A patent/CN110563747A/zh active Pending
- 2015-06-19 US US15/320,656 patent/US20170197985A1/en not_active Abandoned
- 2015-06-19 AU AU2015276860A patent/AU2015276860B2/en active Active
-
2016
- 2016-11-23 IL IL249161A patent/IL249161B/en active IP Right Grant
- 2016-12-14 PH PH12016502499A patent/PH12016502499B1/en unknown
- 2016-12-16 SV SV2016005339A patent/SV2016005339A/es unknown
- 2016-12-16 CL CL2016003249A patent/CL2016003249A1/es unknown
- 2016-12-16 DO DO2016000327A patent/DOP2016000327A/es unknown
- 2016-12-19 ZA ZA2016/08744A patent/ZA201608744B/en unknown
- 2016-12-21 EC ECIEPI201695566A patent/ECSP16095566A/es unknown
-
2017
- 2017-06-15 US US15/624,166 patent/US10385067B2/en active Active
-
2018
- 2018-03-13 CY CY20181100305T patent/CY1120025T1/el unknown
- 2018-04-25 JP JP2018083840A patent/JP2018162246A/ja active Pending
- 2018-05-08 AU AU2018203175A patent/AU2018203175B2/en active Active
-
2020
- 2020-01-24 JP JP2020010135A patent/JP2020097593A/ja active Pending
-
2022
- 2022-03-15 JP JP2022039909A patent/JP2022095640A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE036928T2 (hu) | Nátrium-(2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorbenzil)karbamoil)- 2,3,4,5,7,9,13,13a-oktahidro-2,5-metanopirido[l',2':4.5]pirazino[2,l-b]oxazepin-8-olát | |
| DK3355884T3 (da) | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler | |
| PL3564244T3 (pl) | Krystaliczne postacie (2r,5s,13ar)-8-hydroksy-7,9-diokso-n-(2,4,6-trifluorobenzylo)-2,3,4,5,7,9,13,13a-oktahydro-2,5-metanopirydo[1’,2’:4,5]pirazyno[2,1-b][1,3]oksazepino-10-karboksyamidu | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| LT4056557T (lt) | Benzazepino dariniai, naudotini kaip vaistai | |
| HRP20180585T1 (hr) | Spojevi 2,7-diazaspiro[3.5]nonana | |
| BR112016021231A2 (pt) | derivados de hexose, preparação e uso destes. | |
| TH1601001194A (th) | อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่ | |
| TH1601000114A (th) | อนุพันธ์ไทอีโน [3,2-d] ไพริมิดีน สำหรับการบำบัดการติดเชื้อไวรัส | |
| LT3394053T (lt) | (4-hidriksi-2-fenil-1,3-tiazol-5-il)metanono dariniai kaip trpm8 antagonistai | |
| TH1401005856A (th) | สารอนุพันธ์ไธอีโนไพริมิดีนชนิดใหม่, กระบวนการสำหรับการเตรียมของสารนั้น และ การใช้ในเชิงบำบัดของสารนั้น | |
| HK1235402A1 (en) | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide | |
| HK1233268A1 (en) | Hexose derivatives, preparation and uses thereof | |
| AU2015900153A0 (en) | Improved Finger Ring, tick-tweezers. | |
| TH1501007650A (th) | โพลิยูรีเทนที่เสถียร, ปล่อยสารมลพิษต่ำ |